Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
There is currently an urgent need for effective and safe treatments of Coronavirus Disease
(COVID) - 19 and the cytokine storm that is responsible for the development of patient's
Acute Respiratory Distress Syndrome (ARDS).
As Bronchipret has been proven to be a very safe medicine, it is not expected that it would
lead to the development of severe adverse effects in COVID-19 patients. Bronchipret can
therefore be recommended as effective and safe supplementary treatments of COVID-19, even
more so considering the positive effects shown in vitro. Thus, this randomized study is
conducted to assess the effect of Bronchipret on the immune response and recovery in patients
with mild COVID-19 by assessing several blood parameters as well as the symptom recovery and
improvement in comparison to patients who do not receive Bronchipret. Another aim of this
feasibility study is to determine the best possible primary endpoint, i.e. which shows the
greatest effect according to Cohen.